Why Greenway Medical Technologies Inc. Shares Popped

Why Greenway Medical Technologies Inc. Shares Popped

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.

What: Shares of Greenway Medical Technologies Inc. soared 18% today after private equity firm Vista Equity Partners agreed to acquire the medical software provider for $644 million.

So what: The all-cash deal values Greenway at $20.35 per share and represents a 19% premium to its closing price on Monday. Following the close of the transaction, the combined company, which will be known as Greenway Medical Technologies, will serve about 13,000 medical organizations and 100,000 providers.

Now what: Greenway expects the transaction to close in the fourth quarter of 2013.

"We are pleased to approve this agreement and look forward to completing this transaction," said Greenway founder and Chairman W. Thomas Green. "It provides substantial cash value for our stockholders, and reflects our deep commitment to drive innovation that helps health care professionals succeed and thrive in today's evolving health care landscape."

So while Greenway is likely all popped out at this point, close rivals like Allscripts and athenahealth might be worth looking into for some healthy hidden value.

More compelling health care picks
Obamacare is rewriting the rules for the health care industry, and in the process of doing so, it's creating massive opportunities for investors to get ridiculously rich. How? By investing in a handful of specific health care stocks. In this free report, our analysts walk you through these opportunities and the companies that are positioned to exploit them. The informational edge contained in it is invaluable, but can only be exploited profitably while the rest of the market remains in the dark. To access this free report instantly, simply click here now.

The article Why Greenway Medical Technologies Inc. Shares Popped originally appeared on Fool.com.

Fool contributor Brian Pacampara has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Originally published